Vivos Therapeutics (VVOS)
(Delayed Data from NSDQ)
$3.08 USD
-0.14 (-4.35%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $3.05 -0.03 (-0.97%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.08 USD
-0.14 (-4.35%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $3.05 -0.03 (-0.97%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Here Is Why Bargain Hunters Would Love Fast-paced Mover Vivos Therapeutics, Inc. (VVOS)
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Vivos Therapeutics, Inc. (VVOS) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Here's Why Vivos Therapeutics, Inc. (VVOS) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Vivos Therapeutics, Inc. (VVOS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Vivos Therapeutics, Inc. (VVOS)
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Vivos Therapeutics, Inc. (VVOS) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vivos Therapeutics, Inc. (VVOS) delivered earnings and revenue surprises of -17.65% and 3.96%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 12.50% and 3.97%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?
Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of -7.50% and 175%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 12.99% and 94.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 11.76% and 2.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Exscientia PLC Sponsored ADR (EXAI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Exscientia PLC Sponsored ADR (EXAI) delivered earnings and revenue surprises of -72.73% and 47.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Impel Pharmaceuticals Inc. (IMPL) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of -50.57% and 40.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Chinook Therapeutics (KDNY) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Chinook (KDNY) delivered earnings and revenue surprises of -33.87% and 614.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 2.56% and 1.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
PLx Pharma, Inc. (PLXP) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 7.14% and 86.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Baudax Bio, Inc. (BXRX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Baudax Bio, Inc. (BXRX) delivered earnings and revenue surprises of 17.32% and 61.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 5.75% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of -22.86% and 46.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics (CORT) Q2 Earnings Lag Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of -4% and 1.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Scynexis (SCYX) delivered earnings and revenue surprises of 31.08% and 1.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Vivos (VVOS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Vivos (VVOS) stock based on the movements in the options market lately.